Long-term data highlights sustained symptom improvement in patients with refractory knee osteoarthritis
KiOmed Pharma announces the publication of its PIONEER clinical study in Osteoarthritis and Cartilage Open, a peer-reviewed journal dedicated to advancing osteoarthritis research. The study presents 12-month clinical outcomes for KioMedinevsone, a carboxymethyl-chitosan–based fluid implant developed for the symptomatic management of knee osteoarthritis.
Conducted in Belgium under the supervision of Dr. Philippe Van Overschelde (AZ Maria Middelares, Ghent), the randomized trial evaluated the safety and efficacy of a single injection of carboxymethyl-chitosan in 104 patients with refractory knee osteoarthritis. Participants included individuals with patellofemoral involvement, obesity, and cases typically considered total knee arthroplasty — patient populations often underserved by conventional therapies — patient populations often underserved by conventional therapies.
“Managing refractory knee osteoarthritis remains a clinical challenge” said Dr. Van Overschelde. “In patients with complex profiles, including patellofemoral OA involvement, I observed a consistent improvement in symptoms that was maintained over 12 months. This continuity of benefit is something we rarely see in clinical routine. The results observed with carboxymethyl chitosan suggest a clinically meaningful alternative for managing this challenging subgroup, with a potential to delay surgery,” explains Dr. Van Overschelde.
He further emphasized the clinical importance of long-term outcomes: “In obese OA patients, surgical results are often unpredictable, and the lack of sustained non-surgical options limits our ability to act early. The outcomes observed in this study, bring a promising therapeutic perspective to the management of these difficult patients.”
Houtaï Choumane, CEO of KiOmed Pharma, added: “This publication marks another step in our commitment to bringing science-driven, long-term solutions to people living with osteoarthritis. Seeing the 12-month results of KioMedinevsone recognized in a peer-reviewed setting underscores the relevance of our innovation in real-world clinical practice.”
The full study is available online in Osteoarthritis and Cartilage Open via open access.
📄 Twelve-month efficacy of carboxymethyl-chitosan in refractory knee osteoarthritis: A randomized controlled trial (PIONEER)
🔗 https://www.oarsiopenjournal.com/article/S2665-9131(25)00041-X/fulltext
Want to know more? Contact us : contact@kiomedpharma.com
Discover KioMedinevsone : www.kiomedine.com
